| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Pharmacy OneSource is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Menarini Group is an Italian pharmaceutical company.
Envision Wellness WNY Behavioral Health has been providing counseling and treatment services in WNY for decades to all persons who have requested guidance.
Validation Inc is a Whitehall, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.